

1646
#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopoulos et al. Attorney Docket No.: OMER118473
Application No.: 10/031,546 Group Art Unit: 1646
Filed: January 18, 2002 Examiner: P.M. Mertz
Title: SOLUTIONS AND METHODS FOR INHIBITING CARTILAGE
DEGRADATION

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

March 20, 2003

RECEIVED

MAR 27 2003

TECH CENTER 1600/2900

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.


1. X Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.
3. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

appropriate length required upon the filing of any reply during the entire prosecution of this application.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial No. 206.695.1718


I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on the below date.

Date: 3/20/03


Carole Juleyan

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: G.A. Demopoulos et al. Attorney Docket No. OMER118473
Application No.: 10/031,546 Group Art Unit: 1646
Filed: January 18, 2002 Examiner: P.M. Mertz
Title: SOLUTIONS AND METHODS FOR INHIBITING CARTILAGE
DEGRADATION

RECEIVED

MAR 27 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*Examiner Cite Initials No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
_____ U516	6,096,728		08/01/2000	Collins et al.
_____ U514	6,428,804	B1	08/06/2002	Suzuki et al.

FOREIGN PATENT DOCUMENTS

*Examiner Cite Initial No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
None						

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	Document Information
_____	O0861	Goldring, M.B., "The Role of Cytokines as Inflammatory Mediators in Osteoarthritis: Lessons from Animal Models," <i>Connective Tissue Research</i> , 40 :1-11 (1999).
_____	O1227	Firestein, G.S., et al., "Anticytokine Therapy in Rheumatoid Arthritis," <i>N. Engl. J. Med.</i> 337 :195-197 (1997).
_____	O1268	Talu, G.K., et al., "Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: bupivacaine combination in arthroscopic knee surgery," <i>Knee Surg. Sports Traumatol. Arthrosc.</i> , 6 :355-60 (2002).

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

*Examiner Initial	ID	Document Information
_____	O1281	Muller-Ladner, U., "Gene Transfer of Cytokine Inhibitors Into Human Synovial Fibroblasts in the SCID Mouse Model," <i>Arthritis & Rheumatism</i> , 42(3) :490-497 (1999).
_____	O1282	Osborn, K.E., et al., "Growth Factor Stimulation of Adult Articular Cartilage," <i>Journal of Orthopaedic Research</i> , 7 :35-42 (1989).
_____	O1285	McQuillan, D.J., et al., "Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage," <i>Biochem. J.</i> , 240 :423-430 (1986).
_____	O1357	Barrera, P., et al., "Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF α in patients with rheumatoid arthritis," <i>Ann. Rheum. Dis.</i> , 60 :660-669 (2000).
_____	O1358	Taylor, P.C., "Anti-tumor necrosis factor therapies," <i>Current Opinion in Rheumatology</i> , 13 :164-169 (2001).
_____	O1359	Fautrel, B. et al., "Interet des molecules anti-TNF- α dans le maladies inflammatoires et infectieuses," <i>Rev. Med. Interne</i> , 21 :872-88 (2000).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100